2nd edition. The purpose of this document is to present updated standardized protocols that P. falciparum-endemic countries can use to determine the prevalence of parasites with pfhrp2/3 gene deletions causing negative HRP2 RDT results among symptomatic falciparum patients. The findings should be us...ed to guide RDT selection; more specifically when to shift away from exclusive use of HRP2 to detect P. falciparum infections.
more
The WHO Mekong Malaria Elimination (MME) programme hosted a 3-day meeting on 15–17 November 2023 in Siem Riep, Cambodia for representatives from national malaria programmes, research institutions, partners, donors, WHO and UN agencies. The meeting provided a forum to discuss surveillance systems, ...the future priorities for the WHO Malaria Elimination Database and areas of improvement for data sharing, the efficacy of antimalarial drugs, progress made in malaria elimination, and challenges raised by P. vivax elimination.
more
The following appendices of the Guide for introducing a malaria vaccine containing key messages are available for country adaptation
Guide pour l’introduction du vaccin contre le paludisme dans les programmes nationaux de vaccination
Messages clés sur la vaccination antipaludique à adapter par les pays
Annexe 1. Informations sur le vaccin contre le paludisme destinées aux agents de santé (pour l’introduction du vacci...n et les activités de mise en œuvre en cours)
Annexe 2. Messages clés sur la vaccination antipaludique à l’intention des professionnels de la santé
more
Two malaria vaccines are currently WHO prequalified and recommended1 for use to prevent
P. falciparum malaria in young children, the RTS,S/AS01 vaccine, currently manufactured by
GlaxoSmithKline (GSK), and the R21/Matrix-M vaccine, manufactured by Serum Institute of India
Pvt (SII)
Deux vaccins antipaludiques sont actuellement préqualifiés et recommandés par l'OMS1 pour prévenir
le paludisme à P. falciparum chez les jeunes enfants : le vaccin RTS,S/AS01, actuellement fabriqué par
GlaxoSmithKline (GSK), et le vaccin R21/Matrix-M, fabriqué par Serum Institute of India
...Pvt (SII).
more
Lancet Microbe 2024; 5: e519
Lancet 2024; 403: 533–44
R21/Matrix-M was well tolerated and offered high efficacy against clinical malaria in African children. This
low-cost, high-efficacy vaccine is already licensed by several African countries, and recently received a WHO policy
recommendation and prequalification, offerin...g large-scale supply to help reduce the great burden of malaria in sub-
Saharan Africa.
more
WHO position paper on malaria vaccines, Weekly Epidemiological Record 10 May 2024
The WHO susceptibility test kit has been extensively used for monitoring of insecticide resistance in disease vectors for many years. Over the years, users have reported issues with these kits and potential improvements to WHO in an ad-hoc manner. To systematically determine whether the reported iss...ues were widespread and to collate potential improvements to the kit, a survey of users was put online from 30 June to 15 October 2023. The results from this survey are reported in this report.
more
The aim of this protocol is to support the conduct of entomological comparative efficacy assessments for vector control products and the associated non-inferiority analysis. This evidence is used to inform discussions within the guidelines development context as to whether a new vector control prod...uct should be considered as covered by one or more existing WHO recommendations or not. Alternatively, the evidence may inform the extension of an existing WHO recommendation or the development of a new one, provided that non-inferiority is demonstrated
more
The purpose of the guideline is to provide information to stakeholders on the necessary requirements for a complete prequalification dossier for insecticide-treated nets (ITNs). Its aim is to establish the baseline for dossier requirements which are necessary to assess ITN products for the purposes ...of prequalification, describe the data requirements for fulfilling each dossier module, and to provide standardized information for applicants and testing facilities generating data for ITN prequalification dossiers. The document is supported by implementation guidance documents which provide specific information and considerations for how applicants may approach the generation of supporting information and compilation of a complete product dossier.
more
Medicine 2024;103:29(e39010. This review underscores the urgency of adapting to the changing landscape of malaria transmission driven by climate change. It emphasizes the significance of proactively addressing climate-related challenges to enhance malaria control and protect the health and well-bein...g of vulnerable populations.
more
This paper is the first quantitative analysis of how the impact of extreme weather events, such as floods and cyclones, affects the malaria burden on the continent, as well as the implications of long-onset climate change. This research involved developing a climate model to predict changes in inten...sity, duration, and frequency of floods and cyclones across the continent
more
Reprogramming examples for GC7. This document supports the introduction of climate change-related interventions
into programs to reduce transmission of malaria and protect vulnerable populations.
Thematic brief. Climate change and malaria are two defining challenges of our generation. Both affect disproportionately the
poorest and the most vulnerable, especially in Africa, and may further jeopardize human wellbeing in the future
In recent decades we have seen progressive changes to global climate patterns caused by anthropogenic impacts on the environment. These are likely to directly and indirectly affect human health, and are projected to continue and potentially
accelerate into the future. Neglected tropical diseases (N...TDs) and malaria are potentially particularly sensitive to these changes as they
are prevalent amongst vulnerable populations
in countries expected to experience the greatest
environmental change in the coming decade.
more
